Share
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the EU on 6th January 2021. The patent number is EP3341754. This reinforces the first patent grant which was in the USA back in January 2020. The company has further patents pending in key large countries which have high numbers of radiotherapy cancer treatment centres.
on PATENTSCOP
on Espacenet
Related Posts
Mount Vernon Cancer Centre pioneers first internal invivo dosimetry with TRUEnvivo® DOSEmapper™, revolutionising radiotherapy precision, patient safety, and treatment accuracy.
Dr. Shakar Jafari recognized by Business Leader magazine among UK's inspiring entrepreneurs, highlighting entrepreneurial journey and innovation.
TrueInvivo's implant improves cancer treatment accuracy, accessible globally, supported by UKTI Sirius Programme.
Dr. Shakardokht Jafari presents DOSEmapper™ at IPEM conference after ESTRO, highlighting glass beads' innovation in dosimetry.
